Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aziza
Branford, Connecticut, United Statesazizasf.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate ATR‑12 (engineered S. epidermidis) in Phase 1b trial for Netherton syndrome; ATR‑04 advancing toward Phase 1/2 trial for EGFRi-associated rash; both programs leverage proprietary live biotherapeutic/protein engineering platform. No approved products yet.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Live biotherapeutic product therapyEngineered protein therapyPeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Bayer AG (“Leaps by Bayer”), joint development agreement focused on skin microbiome therapies and consumer products
Beyond the preview
Go deeper on Aziza.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aziza.